A Phase 2 Efficacy And Safety Study Of SU011248 Administered In A Continuous Daily Regimen In Patients With Advanced Gastrointestinal Stromal Tumor
- Histopathologically proven diagnosis of malignant GIST that was not amenable to
- Failed prior treatment with imatinib mesylate, defined either by progression of
disease (according to Response Evaluation Criterion in Solid Tumors (RECIST)
or World Health Organization (WHO) criteria), or by significant toxicity during
treatment with imatinib mesylate that precluded further treatment. Intolerance to
prior imatinib mesylate therapy was defined as follows:
- Life-threatening adverse events (ie, Grade 4) at any dose (attempt to dose reduce or
rechallenge not required) or Unacceptable toxicity induced by a moderate dose (eg,
400 mg/day), specifically, Grade 2 toxicity that was unacceptable to the patient
(such as nausea) that persisted despite standard countermeasures
- Evidence of unidimensionally measurable disease.
- Previous treatment on a SU011248 clinical trial.
- Diagnosis of any second malignancy within the last 3 years, except basal cell
carcinoma, squamous cell skin cancer, or in situ carcinoma, that had been adequately
treated with no evidence of recurrent disease for 12 months.
- History of or known brain metastases, spinal cord compression, or carcinomatous
meningitis, or new evidence of brain or leptomeningeal disease.
- Any of the following within the 12 months prior to starting the study treatment:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, congestive heart failure, cerebrovascular accident or transient ischemic
attack, or pulmonary embolism.
- Ongoing cardiac dysrhythmias of grade 2, atrial fibrillation of any grade, or QTc
interval >450 msec for males or >470 msec for females.
- Hypertension that could not be controlled by medications (>150/100 mm/Hg despite
optimal medical therapy).